CFN Media

November 14, 2016 09:11 ET

Tetra Bio-Pharma (GRPOF) Pioneers a New, Ancient Approach to Cannabinoid Delivery -- CFN Media

SEATTLE, WA--(Marketwired - Nov 14, 2016) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, published a story today highlighting the efforts of Tetra Bio-Pharma Inc. (OTC PINK: GRPOF) (CSE: TBP) to bring smokable, natural medical marijuana to market along with a number of other products targeting chronic pain, insomnia, PTSD, anxiety, and other conditions.

Marijuana-infused edibles have become a popular way to consume THC and CBDs without smoking the dried plant, but there are some key differences in the way that the drug is metabolized that could impact its medicinal value.

The liver metabolizes edible THC, producing an active metabolite that is very effective at crossing the blood-brain barrier where it eventually produces a 'high' feeling. By contrast, inhaled THC bypasses the liver and stomach and travels directly to the brain where it produces a faster high that diminishes more quickly. Inhaled cannabis also leads to higher concentrations of THC in the blood, which tends to be roughly 50-60% compared to just 10-20% for edibles.

These dynamics are important to consider from a medical perspective. The delay between the ingestion of edible THC and the onset of the 'high' effects could lead to overconsumption among patients. Individual differences in metabolism also make it difficult to come up with specific dosing and instructions applicable to everyone. By comparison, the instantaneous effects of inhaled cannabis enables patients to adjust their dosing as needed.

Tetra Bio-Pharma wants to prove that smokable medical marijuana has a place in healthcare by conducting rigorous clinical studies. While GW Pharmaceuticals plc and others have secured approval for cannabis derivatives, nobody has proven to regulators that smokable cannabis has any medical benefits, which is why it remains a Schedule I Controlled Substance in the United States and illegal in other countries.

The company believes that its smokable medical marijuana would provide patients with a better natural alternative to synthesized chemical concoctions being developed by other companies in the space. With so many patients already using smokable medical marijuana, the company has access to a wide patient population where it can draw data to support its clinical studies and ultimately secure regulatory approvals.

In addition to smokable marijuana, the company is pursuing a number of other clinical programs designed to leverage the botanical rather than a synthetic. Its PPP002 program is a Phase III botanical drug that is targeting insomnia in chronic pain patients, while its PPP003 is a combination oral product designed to treat chronic pain, PTSD, and neurological conditions.

Follow the link to read the full article on CannabisFN:

Learn how to become a CFN Media client company, brand or entrepreneur:

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand:

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:

About CFN Media

CFN Media (CannabisFN), the leading creative agency and media network dedicated to legal cannabis, helps marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

About Tetra Bio-Pharma Inc.

Tetra Bio-Pharma is a Canadian Bio Pharmaceutical company at the forefront of Cannabis based pharmaceutical development. The company recently received a research grant from the federal government and will be working with McGill University to develop both prescription and over the counter products. The first product, ppp001, will begin clinical trials in Q4 2016.


Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

Contact Information